New Research Presented by MD Anderson and University of Utah Verifies Dry Connections with PhaSeal
New evidence-based research was presented at ONS Congress by MD Anderson and the University of Utah which concluded only the PhaSeal System confined the drug, thus proving the prevention of drug exposure from preparation through administration of hazardous drugs.
Columbus, OH, May 05, 2007 --(PR.com)-- Specifically, this research determines whether or not transfer devices currently offered have the potential to allow drugs to escape into the environment during the preparation and administration phases of hazardous drugs handling. Thus, putting healthcare workers and those within the environment of care at risk for exposure to these agents.
Susan Spivey Pharmacy Manager, Ambulatory Treatment Center at the University of Texas MD Anderson Cancer Center and Jim Jorgenson, Administrative Director of Pharmacy Services at the University of Utah Huntsman Cancer Center and, each performed the following test at their respective institutions:
Three transfer devices were tested by using fluorescein to determine which device allows leakage and spills during preparation and administration (all 3 devices were used as specified by manufacturer instructions). During procedures, the vial adaptor and syringe components were disengaged, observed and photographed under UV light and then touched to a 4x4 gauze pad. The visual and touch inspections were used to determine presence of contamination.
The three devices tested were the Alaris System (Texium Male Leur and Smartsite® Vented Vial Access Device) by Cardinal Health, the Tevadaptor System (Vial Adaptor and Syringe Adaptor) by Teva Medical, Ltd. and the PhaSeal® System (Protector, Injector Luer Lock and Y-site Connector) by Carmel Pharma.
Only the PhaSeal System by Carmel Pharma, maintained dry connections. No leakage was observed during any of the preparation or administration manipulations. Only the PhaSeal System confined the drug, thus proving the prevention of drug exposure.
“With the introduction of new transfer devices in the market, I chose to replicate the fluorescein study that I conducted back in 2002 to see which devices truly provide the protection needed and meet the definition of closed,” Spivey says, “as in the original study, the PhaSeal system proved the prevention of drug exposure. Both the Tevadaptor System (now marketed by B.Braun as the OnGuard System) and the Cardinal Health/Alaris System showed contamination during all manipulations.”
To obtain a copy of this research abstract, please visit www.carmelpharmausa.com.
University Health Care is the only academic health care system in the Intermountain West. As part of that system, University Hospitals & Clinics offer services in more than 120 specialties and is consistently ranked as one of the country’s best hospitals by U.S. News & World Report. The system provides care for Utahans and residents of five surrounding states in a referral area encompassing more than 10 percent of the continental United States. The hospitals and clinics log more than 900,000 outpatient visits and more than 23,000 inpatient admissions each year. Its academic partners at the University of Utah School of Medicine and Colleges of Nursing, Pharmacy, and Health are internationally regarded research and teaching institutions.
The PhaSeal System is the only clinically proven closed-system drug transfer device available today, offering over 10 peer-reviewed, independent studies. It is manufactured by Carmel Pharma ab in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the U.S. since 2000 and has been implemented in over 500 cancer centers, oncology practices, specialty pharmacies in the United States, including M.D. Anderson in Houston, TX, Texas Children’s and UCSF. If you have questions regarding the PhaSeal System or Carmel Pharma, Inc., please contact Christine Crooks, Director of Marketing at 1-866-487-9250 ext.202, or email us at info@carmelpharmausa.com.
###
Susan Spivey Pharmacy Manager, Ambulatory Treatment Center at the University of Texas MD Anderson Cancer Center and Jim Jorgenson, Administrative Director of Pharmacy Services at the University of Utah Huntsman Cancer Center and, each performed the following test at their respective institutions:
Three transfer devices were tested by using fluorescein to determine which device allows leakage and spills during preparation and administration (all 3 devices were used as specified by manufacturer instructions). During procedures, the vial adaptor and syringe components were disengaged, observed and photographed under UV light and then touched to a 4x4 gauze pad. The visual and touch inspections were used to determine presence of contamination.
The three devices tested were the Alaris System (Texium Male Leur and Smartsite® Vented Vial Access Device) by Cardinal Health, the Tevadaptor System (Vial Adaptor and Syringe Adaptor) by Teva Medical, Ltd. and the PhaSeal® System (Protector, Injector Luer Lock and Y-site Connector) by Carmel Pharma.
Only the PhaSeal System by Carmel Pharma, maintained dry connections. No leakage was observed during any of the preparation or administration manipulations. Only the PhaSeal System confined the drug, thus proving the prevention of drug exposure.
“With the introduction of new transfer devices in the market, I chose to replicate the fluorescein study that I conducted back in 2002 to see which devices truly provide the protection needed and meet the definition of closed,” Spivey says, “as in the original study, the PhaSeal system proved the prevention of drug exposure. Both the Tevadaptor System (now marketed by B.Braun as the OnGuard System) and the Cardinal Health/Alaris System showed contamination during all manipulations.”
To obtain a copy of this research abstract, please visit www.carmelpharmausa.com.
University Health Care is the only academic health care system in the Intermountain West. As part of that system, University Hospitals & Clinics offer services in more than 120 specialties and is consistently ranked as one of the country’s best hospitals by U.S. News & World Report. The system provides care for Utahans and residents of five surrounding states in a referral area encompassing more than 10 percent of the continental United States. The hospitals and clinics log more than 900,000 outpatient visits and more than 23,000 inpatient admissions each year. Its academic partners at the University of Utah School of Medicine and Colleges of Nursing, Pharmacy, and Health are internationally regarded research and teaching institutions.
The PhaSeal System is the only clinically proven closed-system drug transfer device available today, offering over 10 peer-reviewed, independent studies. It is manufactured by Carmel Pharma ab in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the U.S. since 2000 and has been implemented in over 500 cancer centers, oncology practices, specialty pharmacies in the United States, including M.D. Anderson in Houston, TX, Texas Children’s and UCSF. If you have questions regarding the PhaSeal System or Carmel Pharma, Inc., please contact Christine Crooks, Director of Marketing at 1-866-487-9250 ext.202, or email us at info@carmelpharmausa.com.
###
Contact
Carmel Pharma, Inc.
Christine Crooks
866-487-9250
www.carmelpharma.com
Christine Crooks
866-487-9250
www.carmelpharma.com
Contact
Categories